Zimmer Biomet Holdings Capital Expenditures (CapEx) Growth & History (ZBH)
Zimmer Biomet Holdings's capital expenditures (capex) was $224.5M for fiscal 2025.
View full Zimmer Biomet Holdings company overviewZimmer Biomet Holdings annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $224.5M | $20.7M | +10.16% |
| 2024 | 2024-12-31 | $203.8M | −$87.3M | −29.99% |
| 2023 | 2023-12-31 | $291.1M | $103.2M | +54.92% |
| 2022 | 2022-12-31 | $187.9M | $44.3M | +30.85% |
| 2021 | 2021-12-31 | $143.6M | $31.7M | +28.33% |
| 2020 | 2020-12-31 | $111.9M | −$95.2M | −45.97% |
| 2019 | 2019-12-31 | $207.1M | $44.4M | +27.29% |
| 2018 | 2018-12-31 | $162.7M | $6.7M | +4.29% |
| 2017 | 2017-12-31 | $156.0M | −$28.7M | −15.54% |
| 2016 | 2016-12-31 | $184.7M | $17.0M | +10.14% |
| 2015 | 2015-12-31 | $167.7M | $22.8M | +15.73% |
| 2014 | 2014-12-31 | $144.9M | $44.9M | +44.90% |
| 2013 | 2013-12-31 | $100.0M | −$14.7M | −12.82% |
| 2012 | 2012-12-31 | $114.7M | $900,000 | +0.79% |
| 2011 | 2011-12-31 | $113.8M | $34.6M | +43.69% |
| 2010 | 2010-12-31 | $79.2M | −$25.9M | −24.64% |
| 2009 | 2009-12-31 | $105.1M | −$144.9M | −57.96% |
| 2008 | 2008-12-31 | $250.0M | $57.3M | +29.74% |
| 2007 | 2007-12-31 | $192.7M | — | — |
Zimmer Biomet Holdings quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $54.2M | $4.1M | +8.18% |
| Q1 2026 | 2026-03-31 | $36.3M | −$8.3M | −18.61% |
| Q4 2025 | 2025-12-31 | $74.8M | $23.3M | +45.24% |
| Q3 2025 | 2025-09-30 | $55.0M | $10.5M | +23.60% |
| Q2 2025 | 2025-06-30 | $50.1M | −$2.6M | −4.93% |
| Q1 2025 | 2025-03-31 | $44.6M | −$10.5M | −19.06% |
| Q4 2024 | 2024-12-31 | $51.5M | −$11.3M | −17.99% |
| Q3 2024 | 2024-09-30 | $44.5M | −$39.8M | −47.21% |
| Q2 2024 | 2024-06-30 | $52.7M | −$44.6M | −45.84% |
| Q1 2024 | 2024-03-31 | $55.1M | $8.4M | +17.99% |
| Q4 2023 | 2023-12-31 | $62.8M | −$600,000 | −0.95% |
| Q3 2023 | 2023-09-30 | $84.3M | $37.1M | +78.60% |
| Q2 2023 | 2023-06-30 | $97.3M | $56.4M | +137.90% |
| Q1 2023 | 2023-03-31 | $46.7M | $10.3M | +28.30% |
| Q4 2022 | 2022-12-31 | $63.4M | $14.2M | +28.86% |
| Q3 2022 | 2022-09-30 | $47.2M | $3.2M | +7.27% |
| Q2 2022 | 2022-06-30 | $40.9M | $16.3M | +66.26% |
| Q1 2022 | 2022-03-31 | $36.4M | $10.6M | +41.09% |
| Q4 2021 | 2021-12-31 | $49.2M | $27.1M | +122.62% |
| Q3 2021 | 2021-09-30 | $44.0M | $13.4M | +43.79% |
| Q2 2021 | 2021-06-30 | $24.6M | $5.6M | +29.47% |
| Q1 2021 | 2021-03-31 | $25.8M | −$14.4M | −35.82% |
| Q4 2020 | 2020-12-31 | $22.1M | −$29.7M | −57.34% |
| Q3 2020 | 2020-09-30 | $30.6M | −$28.0M | −47.78% |
| Q2 2020 | 2020-06-30 | $19.0M | −$39.9M | −67.74% |
| Q1 2020 | 2020-03-31 | $40.2M | $2.4M | +6.35% |
| Q4 2019 | 2019-12-31 | $51.8M | $4.3M | +9.05% |
| Q3 2019 | 2019-09-30 | $58.6M | −$2.9M | −4.72% |
| Q2 2019 | 2019-06-30 | $58.9M | $31.9M | +118.15% |
| Q1 2019 | 2019-03-31 | $37.8M | $11.1M | +41.57% |
| Q4 2018 | 2018-12-31 | $47.5M | $1.3M | +2.81% |
| Q3 2018 | 2018-09-30 | $61.5M | $25.5M | +70.83% |
| Q2 2018 | 2018-06-30 | $27.0M | −$3.7M | −12.05% |
| Q1 2018 | 2018-03-31 | $26.7M | −$16.4M | −38.05% |
| Q4 2017 | 2017-12-31 | $46.2M | −$8.4M | −15.38% |
| Q3 2017 | 2017-09-30 | $36.0M | −$20.4M | −36.17% |
| Q2 2017 | 2017-06-30 | $30.7M | −$15.4M | −33.41% |
| Q1 2017 | 2017-03-31 | $43.1M | $15.5M | +56.16% |
| Q4 2016 | 2016-12-31 | $54.6M | $5.5M | +11.20% |
| Q3 2016 | 2016-09-30 | $56.4M | $2.6M | +4.83% |
| Q2 2016 | 2016-06-30 | $46.1M | $15.7M | +51.64% |
| Q1 2016 | 2016-03-31 | $27.6M | −$6.8M | −19.77% |
| Q4 2015 | 2015-12-31 | $49.1M | −$100,000 | −0.20% |
| Q3 2015 | 2015-09-30 | $53.8M | $21.5M | +66.56% |
| Q2 2015 | 2015-06-30 | $30.4M | −$1.6M | −5.00% |
| Q1 2015 | 2015-03-31 | $34.4M | $3.0M | +9.55% |
| Q4 2014 | 2014-12-31 | $49.2M | $26.4M | +115.79% |
| Q3 2014 | 2014-09-30 | $32.3M | −$4.6M | −12.47% |
| Q2 2014 | 2014-06-30 | $32.0M | $9.6M | +42.86% |
| Q1 2014 | 2014-03-31 | $31.4M | $13.5M | +75.42% |
| Q4 2013 | 2013-12-31 | $22.8M | −$20.5M | −47.34% |
| Q3 2013 | 2013-09-30 | $36.9M | $9.8M | +36.16% |
| Q2 2013 | 2013-06-30 | $22.4M | −$2.4M | −9.68% |
| Q1 2013 | 2013-03-31 | $17.9M | −$1.6M | −8.21% |
| Q4 2012 | 2012-12-31 | $43.3M | −$2.7M | −5.87% |
| Q3 2012 | 2012-09-30 | $27.1M | −$6.7M | −19.82% |
| Q2 2012 | 2012-06-30 | $24.8M | $7.9M | +46.75% |
| Q1 2012 | 2012-03-31 | $19.5M | $2.4M | +14.04% |
| Q4 2011 | 2011-12-31 | $46.0M | $7.4M | +19.17% |
| Q3 2011 | 2011-09-30 | $33.8M | $19.9M | +143.17% |
| Q2 2011 | 2011-06-30 | $16.9M | $1.8M | +11.92% |
| Q1 2011 | 2011-03-31 | $17.1M | $5.5M | +47.41% |
| Q4 2010 | 2010-12-31 | $38.6M | $10.3M | +36.40% |
| Q3 2010 | 2010-09-30 | $13.9M | −$8.2M | −37.10% |
| Q2 2010 | 2010-06-30 | $15.1M | −$8.7M | −36.55% |
| Q1 2010 | 2010-03-31 | $11.6M | −$19.3M | −62.46% |
| Q4 2009 | 2009-12-31 | $28.3M | — | — |
| Q3 2009 | 2009-09-30 | $22.1M | −$45.6M | −67.36% |
| Q2 2009 | 2009-06-30 | $23.8M | — | — |
| Q1 2009 | 2009-03-31 | $30.9M | — | — |
| Q3 2008 | 2008-09-30 | $67.7M | — | — |
Zimmer Biomet Holdings capital expenditures (capex) trends
Over the last five fiscal years, Zimmer Biomet Holdings's capital expenditures (capex) increased from $111.9M to $224.5M, a change of $112.6M. The latest reported quarter, Q2 2026, shows $54.2M.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Zimmer Biomet Holdings source filings ↗